A structural basis for mutational inactivation of the tumour suppressor Smad4
- PMID: 9214508
- DOI: 10.1038/40431
A structural basis for mutational inactivation of the tumour suppressor Smad4
Abstract
The Smad4/DPC4 tumour suppressor is inactivated in nearly half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. Smad4/DPC4, and the related tumour suppressor Smad2, belong to the SMAD family of proteins that mediate signalling by the TGF-beta/activin/BMP-2/4 cytokine superfamily from receptor Ser/Thr protein kinases at the cell surface to the nucleus. SMAD proteins, which are phosphorylated by the activated receptor, propagate the signal, in part, through homo- and hetero-oligomeric interactions. Smad4/DPC4 plays a central role as it is the shared hetero-oligomerization partner of the other SMADs. The conserved carboxy-terminal domains of SMADs are sufficient for inducing most of the ligand-specific effects, and are the primary targets of tumorigenic inactivation. We now describe the crystal structure of the C-terminal domain (CTD) of the Smad4/DPC4 tumour suppressor, determined at 2.5 A resolution. The structure reveals that the Smad4/DPC4 CTD forms a crystallographic trimer through a conserved protein-protein interface, to which the majority of the tumour-derived missense mutations map. These mutations disrupt homo-oligomerization in vitro and in vivo, indicating that the trimeric assembly of the Smad4/DPC4 CTD is critical for signalling and is disrupted by tumorigenic mutations.
Comment in
-
Signal transduction. Mad about SMADs.Nature. 1997 Jul 3;388(6637):28-9. doi: 10.1038/40290. Nature. 1997. PMID: 9214496 No abstract available.
Similar articles
-
DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells.Oncogene. 1997 Apr 24;14(16):1891-9. doi: 10.1038/sj.onc.1201017. Oncogene. 1997. PMID: 9150356
-
Functional mapping of the MH1 DNA-binding domain of DPC4/SMAD4.Nucleic Acids Res. 2000 Jun 15;28(12):2363-8. doi: 10.1093/nar/28.12.2363. Nucleic Acids Res. 2000. PMID: 10871368 Free PMC article.
-
Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4.J Biol Chem. 2003 May 23;278(21):18714-9. doi: 10.1074/jbc.M302243200. Epub 2003 Mar 5. J Biol Chem. 2003. PMID: 12621041
-
DPC4/SMAD4 gene alterations in human cancer, and their functional implications.Ann Oncol. 1999;10 Suppl 4:56-9. Ann Oncol. 1999. PMID: 10436786 Review.
-
Role of Smad4 (DPC4) inactivation in human cancer.Biochem Biophys Res Commun. 2003 Jul 11;306(4):799-804. doi: 10.1016/s0006-291x(03)01066-0. Biochem Biophys Res Commun. 2003. PMID: 12821112 Review.
Cited by
-
Phenotypic characterisation of SMAD4 variant carriers.J Med Genet. 2024 Jul 19;61(8):734-740. doi: 10.1136/jmg-2023-109632. J Med Genet. 2024. PMID: 38575304 Free PMC article.
-
EMT Dynamics in Lymph Node Metastasis of Oral Squamous Cell Carcinoma.Cancers (Basel). 2024 Mar 18;16(6):1185. doi: 10.3390/cancers16061185. Cancers (Basel). 2024. PMID: 38539520 Free PMC article.
-
The TGF-β superfamily as potential therapeutic targets in pancreatic cancer.Front Oncol. 2024 Mar 4;14:1362247. doi: 10.3389/fonc.2024.1362247. eCollection 2024. Front Oncol. 2024. PMID: 38500662 Free PMC article. Review.
-
Unexpected Differences in the Speed of Non-Malignant versus Malignant Cell Migration Reveal Differential Basal Intracellular ATP Levels.Cancers (Basel). 2023 Nov 22;15(23):5519. doi: 10.3390/cancers15235519. Cancers (Basel). 2023. PMID: 38067222 Free PMC article.
-
Multi-omic stratification of the missense variant cysteinome.bioRxiv [Preprint]. 2023 Aug 14:2023.08.12.553095. doi: 10.1101/2023.08.12.553095. bioRxiv. 2023. PMID: 37645963 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
